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Results: Statistical analysis indicates a signiﬁcant improvement
in both the experimental and wait-list control group on all
primary outcome measures following NMT treatment. The wait-
list control group demonstrated no signiﬁcant improvement on
test measures over baseline scores during the wait period. No
adverse reactions were reported.
Conclusions: These ﬁndings suggest that NMT is a promis-
ing intervention for autism that has the potential to produce a
signiﬁcant reduction in maladaptive behaviors and a signiﬁ-
cant increase in adaptive behaviors within a relatively short
period of time.
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Autism spectrum disorder (ASD) is a complex clinical
syndrome that usually manifests during the ﬁrst three years
of life and typically lasts throughout a person's lifetime.
It is characterized by restricted activities and interests,
repetitive patterns of behavior, impairments in social inter-
action, and impairments in communication.1 Recentadvances in the genetics of autism emphasize its etiological
heterogeneity, with each genetic susceptibility locus
accounting for only a small fraction of cases or having
only a small effect. Therefore, it is not surprising that no
unifying structural or neuropathological features have been
conclusively identiﬁed.2
Autism diagnoses have been rising steadily over the past
several decades. Data from 2008 indicated an ASD prevalence of
1 in 88 children (1 in 54 boys) aged 8 years in fourteen Autism
and Developmental Disabilities Monitoring Sites in the
United States. This prevalence represents an estimated increase
of 78% over the 2002 data3 and a 1000% increase in the past 40
years.4
Lifetime cost estimates of providing care for each person
with autism ranges from $1.4 to $2.3 million, depending on
the level of intellectual disability present. New research
estimates that autism currently costs society $126 billion per
year in the United States, an amount that has more than
tripled since 2006.5 This ﬁgure is based on the 2006 Centers
for Disease Control (CDC) prevalence rate of 1 in 110. These
costs include treatment and medical costs throughout life,
caregiver and social service costs, education costs, lost
productivity of the child, lost productivity of the caregivers,
and adult care.13EXPLORE January/February 2014, Vol. 10, No. 1
http://dx.doi.org/10.1016/j.explore.2013.10.005
As increasing numbers of children are diagnosed with an
autism spectrum disorder, there is a need to ensure that all of
these children have access to and receive appropriate and
personalized medical, educational, occupational, and social
services throughout their lives. In recognition of the major
challenge to public health that ASD presents, the National
Institutes of Health (NIH) has been responding by supporting
robust and innovative research designed to ﬁnd better ways to
identify, treat, and even prevent the disabling symptoms and
to improve the quality of life for people with ASD and their
families.6
There is no fully effective treatment for autism, and current
therapies tend to be expensive and of long duration and may
only yield slow, incremental improvement in functioning.
Many children with ASD are treated with medication, but
little evidence exists indicating signiﬁcant beneﬁt from most
medical treatments.7 The antipsychotics risperidone and
aripiprazole have been demonstrated to reduce hyper-
activity, noncompliance, and repetitive behavior, but both
medications produce signiﬁcant side effects including
marked weight gain, sedation, and risk of extrapyramidal
symptoms.8
Evidence is supportive of early intensive behavioral and
developmental intervention (EIBI) for improving adaptive
behavior, language skills, and cognitive performance in some
children. EIBI is a form of applied behavior analysis treatment
(ABA) that includes the University of California, Los
Angeles/Lovaas model and the Early Start Denver Model.
Dramatic improvements using these types of treatments were
observed in a subset of children and mild improvements in
terms of standardized outcomes were seen in others, but
many children continued to display prominent areas of
impairment. There are few or no studies that directly compare
the effects of different EIBI treatment approaches and their
practical utility or feasibility beyond research studies, nor is
there adequate evidence to characterize the subpopulation of
children who experience positive response to such interven-
tions.8–10
Several types of evidence-based complementary and alter-
native medicine (CAM) therapies for autism have been
proposed, which are primarily based on nutritional interven-
tions, on the reduction of environmental toxins by chelation,
or on mind–body therapies such as music therapy,
yoga, massage, or neurofeedback.11 Most CAM treatments
have not been studied adequately and are not considered
to have enough evidence to support their use.12 While almost
no research in the behavioral, educational, allied health, or
CAM literature reported harms of intervention, assessment
of potential harms is warranted before initiating CAM
treatment,8 especially when serious safety issues are
associated with the use of that therapy, such as with the use
of chelation products. The chemical substances utilized in
chelation treatment have a myriad of potentially serious side
effects such as fever, vomiting, hypertension, hypotension,
cardiac arrhythmias, and hypocalcemia, thus presenting risks
of confounding and dangerous medical conditions.13
Autism does not remit in the great majority of children,
and the development of targeted therapies remains an
important and achievable goal of current research.14 EXPLORE January/February 2014, Vol. 10, No. 1In order to investigate new therapeutic approaches that may
target this disorder at all of its interdependent levels—
physiological, psychological, emotional, and behavioral—we
conducted a therapeutic trial using a speciﬁc form of
intention-based (or consciousness-based) therapy. In the
context of this method, it is postulated that the mind–body
represents an intelligent self-correcting system that seeks
homeostasis. Any form of pathophysiology may be inter-
preted as a type of impaired self-awareness and a compro-
mised ability to adapt to change in its internal and external
environment. By means of focused intention/thought, the
trained therapist is able to investigate the patient's subcon-
scious informational basis and unlock the subconscious
awareness of the potential for more successful regulation.14
We show that this procedure leads to a signiﬁcant and broad
range of improvements in eighteen children diagnosed with
an autistic disorder.INTENTION-BASED THERAPY
NeuroModulation Technique (NMT) is based on the prop-
osition that psychophysiological processes occurring in the
patient are a reﬂection of the perceptual/informational state
of regulatory processing systems of the mind–body. NMT
postulates that the ground on which consciousness manifests
itself is within a universal information ﬁeld that continuously
informs the mind–body, orienting it toward wellness. As an
intelligent self-correcting system that seeks homeostasis, when
pathophysiology occurs, it may be interpreted as some
combination of diminished self-awareness and/or corruption
of its informational status.15
NMT recognizes that the aggregate neurological and
energetic components that regulate body processes function
at a subconscious or other-than-conscious (OTC) level rather
than at a conscious level. OTC information processing occurs
at multiple levels within the central nervous system, the
autonomic nervous system, biological neural networks, and
energetic components that include the meridian system. NMT
refers to this OTC information processing system as the
Autonomic Control System (ACS).
NMT practitioners take the position that the ACS is
intelligent and can comprehend meaningful dialogue that is
directed to it. The practitioner investigates the ACS status by
using Muscle Response Testing (MRT) to identify clinically
relevant query statements/intentions structured upon a clin-
ical topic (such as allergies or immune system functioning).
MRT yields a strong or weak muscle response, which is taken
by the practitioner as an afﬁrmative or negative answer to the
query. Each answer is used to help navigate through an
informational decision tree that leads further in the inves-
tigation of the particular area under consideration.14–16
When areas of less than optimal functioning are identiﬁed,
the practitioner applies a series of relevant corrective inten-
tions designed to inform the patient that more effective ways
of responding to one's internal and/or external environment
are possible. These corrective intentions are taken from the
NMT treatment manual, which consists of approximately 70
clinical algorithms or NMT Clinical Pathways. The ACS
communication is directed to the patient by the focusedIntention-Based Therapy for Autism Spectrum Disorder
mind of the practitioner in such a way that the meaning of
the communication can be immediately perceived and under-
stood by the patient on an OTC level. This query/correction
process is then repeated throughout the session. The ther-
apeutic aim is to facilitate reorganization at the OTC level in
order to produce an optimal informational state leading to
more correct psychophysiology.16
The following is an example of a query/response sequence
taken from the NMT Toxin Pathway: “Is any level of the ACS
fully aware of the existence, identity, and location in the body
of any of the following chemical agents bound to tissues or
chemicals of the body and/or disrupting chemical or ener-
getic signaling in the mind–body?”
MRT is then used to determine if the ACS identiﬁes any
toxin from a list of different categories of possible toxins
(such as heavy metals or volatile organic compounds) as being
present in the body.
When any toxins are identiﬁed, the ACS is then queried,
“Is any level of the ACS fully aware of the capacity of the
ACS to force a purging of these toxins from their binding
sites on body tissues and chemicals, to facilitate their trans-
port away from the tissues, and to expedite their degradation
and elimination from the body?”
If a “yes” response is received to this query, the ACS is then
asked to execute the therapeutic intention of the entire Toxin
Pathway. MRT is used to determine if the ACS has success-
fully executed the therapeutic intention and started the
detoxiﬁcation process for the identiﬁed toxins. The query/
response process may be repeated until the ACS indicates the
pathway is concluded.
A similar procedure is followed for all the NMT pathways.
With the NMT Allergy Pathway, for example, the ACS is
queried to identify any exogenous substance or any endoge-
nous tissue or body chemistry that is contributing to allergy,
autoimmune, or inﬂammatory behavior. The ACS is then
queried to identify all physiological processes contributing to
such behavior, and then a statement is given instructing the
ACS to correct the inappropriate body responses.
Each NMT pathway has a standard protocol that the NMT
practitioner follows when the ACS indicates a particular
pathway is needed. MRT is used to query the patient's
ACS, which dictates the order in which pathways are used
during a session. The sequence of pathways used during an
NMT session may vary between sessions and between
patients.
The MRT used in this study is a type of manual muscle
testing (MMT) derived from Applied Kinesiology (AK), an
evaluation and treatment method based on the discovery that
the musculoskeletal system can be used as an indicator of
functional neurology.17 Since its ﬁrst introduction in 1964,
multiple offshoots of AK have been developed that have
expanded the methodology and applications of MMT.18–20
MMT is considered useful in the assessment of weakness of
muscles directly involved with pain, injury, and neuromus-
culoskeletal disorders, but data is said to be lacking which
demonstrates MMT's generalizability to other applications
such as identiﬁcation of organic disorders, or for other
diagnostic purposes.21,22 Proponents of AK argue that scien-
tiﬁc evidence does support aspects of its scientiﬁc plausibilityIntention-Based Therapy for Autism Spectrum Disorderand validity and that criticism is often directed at studies that
either omit or misinterpret essential elements of AK or have
signiﬁcant methodological issues in their design.20,23
In a previous study, the use of NMT was found to induce
regression of cavitational lesions, a common progressive form
of ischemic disease of the alveolar arch, with an efﬁcacy
comparable to that of surgery. Through-transmission ultra-
sonography and computer imaging was used to document
increase in bone density in the alveolar processes of maxilla
and mandible.14 This outcome was consistent with NMT's
hypothesized mechanism of change of optimizing func-
tioning on an OTC level through the NMT dialogue
process. In the cavitation study, the NMT process was said
to have brought about better mind–body awareness of the
jawbone cavitations, to have produced increased angiogenic
activity at the osteonecrotic sites, to have produced improved
immune system response to pathogens in the lesioned areas,
and to have increased osteogenesis in the alveolar bone.14 A
more detailed description of the rationale and clinical
algorithms underlying intention-based therapies in informa-
tional medicine are beyond the scope of this article, and more
theoretical information can be found elsewhere.14,24–30METHODS
Inclusion and Exclusion Criteria
The Institutional Review Board of the Paciﬁc Graduate
School of Psychology, Palo Alto, CA, approved the protocol
for this study. The protocol was consistent with the Decla-
ration of Helsinki and patients received no compensation.
Male and female children between the ages of 5 and 10 years
of age were recruited from 9 research sites by announcements
sent to local and online autism support groups and contact
with parents as well as schools and professionals who worked
with children with autism.
Qualiﬁed participants were those children who had
received a formal diagnosis of Autistic Disorder (299.00)
from a physician or psychologist using diagnostic criteria
from the Diagnostic and Statistical Manual of Mental Disorders
(revised 4th edition).1 Parents and/or legal guardians were
required to complete an informed consent that included a
videotape release. They were required to supply proof of
autism diagnosis, and children were required to have had their
diagnosis of autism at least one year prior to the date of the
application.
Eligible children were required to have not started any new
therapies or stopped any ongoing therapies designed to treat
their autism such as behavior therapy, speech therapy,
physical therapy, sensory integration, dietary modiﬁcation
or dietary supplementation, or any other alternative or
experimental therapy designed to treat autism in the 6 months
prior to the date of the application for participation. The
purpose of this requirement was to ensure that improvement
in autistic symptoms during the course of this study was not
due to stopping a therapy that may have caused a worsening
of symptoms in the child and to make sure that improvement
seen during the course of the study was not due to a therapy
that was recently started prior to receiving NMT. Also,
children must not have received any previous NMT therapy.EXPLORE January/February 2014, Vol. 10, No. 1 15
Table 1. Treatment Schedule
Schedule Experimental Wait-List Control
Week 1 PDDBI, ABC-C, ATEC PDDBI, ABC-C, ATEC
Week 2 NMT 1, NMT 2
Week 3 NMT 3, NMT 4
Week 4 NMT 5, NMT 6
Week 5 NMT 7, NMT 8
Week 6 NMT 9, NMT 10
Week 7 NMT 11, NMT 12
Week 8 PDDBI, ABC-C, ATEC PDDBI, ABC-C, ATEC
Week 9 NMT 1, NMT 2
Week 10 NMT 3, NMT 4
Week 11 NMT 5, NMT 6
Week 12 NMT 7, NMT 8
Week 13 NMT 9, NMT 10
Week 14 NMT 11, NMT 12
Week 15 PDDBI, ABC-C, ATEC
Note: PDDBI: Pervasive Developmental Disorder Behavioral Inventory;
ABC-C ¼ Aberrant Behavior Checklist, Community Version; ATEC ¼ Autism
Treatment Evaluation Checklist; NMT ¼ NeuroModulation Technique.Children diagnosed with medical conditions such as
cerebral palsy, Down's syndrome, traumatic brain injury,
encephalitis, Lyme disease, cancer, any active infectious
disease, or any chronic medical condition other than autism
(such as Crohn's disease, asthma, and bronchitis) for which
the child had been receiving treatment, medication, and/or
therapy were excluded from participating. Also excluded from
the study were children who have had or were undergoing
chelation therapy, as well as children who have displayed
signiﬁcant self-injurious behavior (children who have caused
visible harm to themselves). Serious self-injurious behavior
could create potentially confounding medical conditions
such as closed head injuries or seizures, broken bones, or
systemic infections from cuts. Children with a history of food
or airborne allergies, sensitivities, or mild digestive problems
were eligible to participate in the study.
Parents and/or legal guardians completed the Autism
Treatment Evaluation Checklist (ATEC). In order to be
eligible for the study, a score of 54 or higher was needed on
the ATEC. Total Score on the ATEC ranges from 0 to 179. A
value of 54, which fell midway between the 34th and 35th
percentile on the published score distribution for the ATEC,
was chosen as a cutoff to ensure that children selected to be in
the study would have sufﬁcient severity of symptoms to
demonstrate treatment effects.31 The average age of the 18
children who participated in the study was 6 years, 11
months. Seventeen children were male and one was female.
Demographic breakdown of the children in the study
included 11 Caucasians, 4 Hispanics, 2 African Americans,
and 1 Asian. For the research sites, once a second child was
recruited, the two children were assigned to either the
experimental or the wait-list control group based on the
home telephone number. The child with the highest last digit
(or if a tie, the successive digit) of the home number was
assigned to the experimental group and the other child was
assigned to the wait-list control group.
The majority of children had received at least 4 different
therapies such as physical therapy, occupational therapy,
speech therapy, sensory integration, or behavior therapy/
applied behavior analysis (ABA) before participating in the
study. The range was from 0 to 9 therapies, with an average of
5.2 therapies. Only one child had never received any previous
treatment for autism.
Study Design
Three outcome instruments were used to determine treatment
effects: the Pervasive Developmental Disorder Behavioral
Inventory (PDDBI), the Aberrant Behavior Checklist-
Community (ABC-C), and the Autism Treatment Evaluation
Checklist (ATEC). Primary efﬁcacy outcome measures
included mean change from start of treatment to end of
treatment on the PDDBI Autism Composite Index, the ABC-
C Total Score, and the ATEC Total Score. Secondary out-
come measures included mean change from start to end of
treatment on the remaining subscales of each of these three
test instruments. Baseline measures were obtained on these
instruments from parents of children in both the experimen-
tal and wait-list control groups at Week 1 of the study. The
treatment schedule is illustrated in Table 1.16 EXPLORE January/February 2014, Vol. 10, No. 1For the experimental group, treatment consisting of
2 NMT sessions a week began at Week 2 and concluded at
Week 7. During Week 8, one week after NMT session
number 12, parents of children in the experimental group
completed the ﬁnal PDDBI, ABC-C, and ATEC. Also during
Week 8, parents of children in the wait-list control group
repeated the baseline measures on the PDDBI, ABC-C, and
ATEC to determine if any positive or negative changes
occurred in their children as a result of the waiting period
to receive NMT treatment. For the wait-list control group,
treatment consisting of 2 NMT sessions a week for 6 weeks
began at Week 9 and concluded at Week 14. During Week
15, one week after NMT session number 12, parents of
children in the wait-list control group completed the ﬁnal
PDDBI, ABC-C, and ATEC.
The average length of an NMT session in the study was 46
minutes, with a total average treatment time of 9.2 hours over
12 sessions.
Data Analyses
A repeated-measures t-test was used to compare treatment
effects in the experimental group from start of treatment to
post-treatment (Table 2), treatment effects in the wait-list
control group from start of treatment to post-treatment
(Table 2), and to measure any changes in the wait-list control
group from baseline to start of treatment (Table 4). A two-
sample t-test was used to determine if experimental vs. wait-
list control group scores on primary outcome measures
differed at the start of treatment for the respective groups
(Table 3).
Statistical analyses were performed for PDDBI, ABC-C,
and ATEC using the standard SAS/STATs Software32 and
GraphPad InStat software.33 A one-sample Kolmogorov–
Smirnov (KS) test was run on each individual data set to
check for normal distribution of data. In cases where one orIntention-Based Therapy for Autism Spectrum Disorder
Table 2. Experimental and Wait-List Control Group Composite Scores on the PDDBI, ABC-C, and ATEC at the start and end of treatment
Experimental Group, n ¼ 9
Start of NMT (Week 1) Post-NMT (Week 8)
Percentage Change t-Test p Value Cohen's dM SD M SD
PDDBI Autism Composite Index 63.00 15.63 48.56 15.32 22.92 3.22 .0123 0.93
ABC-C Total Score 83.44 31.79 47.67 20.40 42.87 4.43 .0022 1.34
ATEC Total Score 82.56 23.72 56.22 22.35 31.90 4.33 .0025 1.14
Wait-List Control Group, n ¼ 9
Start of NMT (Week 8) Post-NMT (Week 15)
Percentage Change t-Test p Value Cohen's dM SD M SD
PDDBI Autism Composite Index 52.44 7.23 41.78 10.21 20.33 3.99 .0040 1.21
ABC-C Total Score 51.11 21.18 33.89 22.86 33.69 3.01 .0169 0.78
ATEC Total Score 69.33 20.08 50.11 22.93 27.72 3.54 .0077 0.89both data sets in a comparison did not pass the individual KS
test for normality, a two-sample KS test was run, and for every
two-sample KS test that was performed, there was no evidence
to support the hypothesis that the two samples came from
different populations. A p o .05 (two-tailed) was considered
signiﬁcant for all analyses.OUTCOME MEASURES
PDDBI
Diagnostic tools for assessing autism such as the Autism
Diagnostic Interview-Revised (ADI-R)34 and the Autism Dia-
gnostic Observation Schedule (ADOS)35 have limitations in
that these instruments were not designed to assess response to
treatment, and the scales do not yield age-standardized scores
that were derived from a normative sample.36 Other scales
have been used in research studies to measure responsiveness
to treatment including the Childhood Autism Rating Scale
(CARS)37 and the Autism Behavior Checklist (ABC),38 but
these rating instruments lack information regarding adaptive
behaviors and only assess problem behaviors. A treatment for
autism (i.e., pharmacological) that suppresses maladaptive
behaviors such as hyperactivity or aggression may be re-
ported as efﬁcacious, but the intervention being studied
also may suppress adaptive behaviors such as social communi-
cation. If test instruments that detect such effects are not
used, faulty conclusions about the true efﬁcacy of the
intervention may be derived.36
The Pervasive Developmental Disorder Behavioral Inven-
tory (PDDBI) was developed speciﬁcally to address theseTable 3. Experimental vs. Wait-List Control Group Composite Score dif
Outcome Measure




PDDBI Autism Composite Index 63.00 15.63 5
ABC-C Total Score 83.44 31.79 5
ATEC Total Score 82.56 23.72 6
Intention-Based Therapy for Autism Spectrum Disorderlimitations with existing autism instruments.36 The PDDBI
assesses response to intervention and includes assessment of
social communication behaviors with age-standardized scor-
ing that is sensitive to developmental change in children
with autism. The PDDBI was standardized on a well-
diagnosed sample and provides a standard T score on each
scale of the PDDBI (mean of 50 and a standard deviation of
10) that measures deviance from the average score shown by
a typical person with autism. A T score of 50 in all domains
is typical of a child with autism of a given age. All items on
the PDDBI are completed on a 4-point Likert scale ranging
from 0 (does not show behavior) to 3 (usually/typically
shows behavior). The PDDBI is published in both a Parent
and a Teacher Rating Form. The Parent Rating Form was
used in this study.
The PDDBI measures 10 domains including 7 Approach-
Withdrawal Problem areas for which higher T scores indicate
increasing level of severity and 3 Receptive/Expressive Com-
munication Skill areas for which higher T scores indicate
increasing competence.
The Approach-Withdrawal Problem areas on the PDDBI
include the following domains: Sensory/Perceptual Approach
Behaviors (SENSORY), Ritualisms/Resistance to Change
(RITUAL), Social Pragmatic Problems (SOCPP), Semantic
Pragmatic Problems (SEMPP), Arousal Regulation Problems
(AROUSE), Speciﬁc Fears (FEARS), and Aggressiveness
(AGG). The Receptive/Expressive Social Communication
Abilities domains include Social Approach Behaviors
(SOCAPP), Expressive Language (EXPRESS), and Learning,
Memory, and Receptive Language (LMRL).ferences on the PDDBI, ABC-C, and ATEC at the start of treatment
-List Control Start of NMT
(Week 8)
Difference
t-Test p ValueM SD M SD
2.44 7.23 10.56 12.18 1.84 0.0846
1.11 21.18 32.33 27.01 2.54 0.0219
9.33 20.08 13.22 21.98 1.28 0.2201
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Table 4. Wait-List Control Group Composite Score change on the PDDBI, ABC-C, and ATEC from baseline to start of treatment
Wait-List Control Group
Baseline (Week 1) Start of NMT (Week 8)
Percentage Change t-Test p ValueM SD M SD
PDDBI Autism Composite Index 51.11 9.02 52.44 7.23 þ2.60 0.73 0.4843
ABC-C Total Score 47.33 22.44 51.11 21.18 þ7.99 1.64 0.1394
ATEC Total Score 68.44 18.85 69.33 20.08 þ1.30 0.27 0.7914The PDDBI has 5 Composite Score indices: 2 for the
Approach-Withdrawal Problem areas for which higher T
scores indicate increasing level of severity (Repetitive, Ritual-
istic & Pragmatic Problem Behaviors Composite—REPRIT/C
and the Approach-Withdrawal Problems Composite—AWP/
C); 2 for the Receptive/Expressive Communication Abilities
areas for which higher T scores indicate increasing compe-
tence (Expressive Social Communication Abilities Composite
—EXSCA/C and the Receptive/Expressive Social Commu-
nication Abilities Composite —REXSCA/C); and an Autism
Composite (AUTISM) which is comprised of the formula
(SENSORY þ RITUAL þ SOCPP þ SEMPP)—(SOCAPP þ
EXPRESS). Higher T scores on the Autism Composite
indicate increasing level of severity.
The PDDBI has been shown to have very good internal
consistency, developmental validity, and construct validity.
The PDDBI Parent Autism Score was signiﬁcantly correlated
with the Childhood Autism Rating Scale (CARS) (r ¼ 0.53,
p o .0001) and all behavioral measures of the Autism
Diagnostic Interview-Revised (ADI-R) Qualitative Impairments
in Reciprocal Social Interaction (QIRSI), r ¼ 0.58, p o .001;
Communication (COM) r ¼ 0.40, p o .001; and Repetitive
Behaviors and Stereotyped Patterns (RSP), r ¼ 0.35, p o .01).
Maladaptive scales from the Parent PDDBI correlated well
with comparable factors of the Nisonger Child Behavior
Rating Form (CBRF). For example, the PDDBI Sensory/
Perceptual Approach Behaviors subscale was correlated most
strongly with the Self-Injury/Stereotypic (r ¼ 0.60, po .0001)
and Hyperactive CBRF factors (r ¼ 0.57, p o .0001).39,40
Adaptive sections of the Parent PDDBI correlated highly
with direct assessments of a child's intellectual functioning on
the Grifﬁths Mental Development Scales (GMDS), with the
PDDBI language scales correlating most strongly with the
GMDS General Quotient (GQ) (PDDBI Social Approach
Behaviors, r ¼ 0.61, p o .0001; PDDBI Learning, Memory.
and Receptive Language, r ¼ 0.74, p o .0001). All of the
adaptive subscales on the Parent PDDBI correlated with the
Vineland Adaptive Behavior Scales (VABS), with the stron-
gest correlations between comparable scales. For example, the
Vineland Communication Scale (CSS) correlated most
strongly with the language subscales on the PDDBI (Seman-
tic/Pragmatic, r ¼ 0.81, p o .0001 and Learning, Memory.
and Receptive Language, r ¼ 0.76, p o .0001).39,40
ABC-C
The aberrant behavior checklist (ABC) was originally designed
to monitor the effects of psychotropic drugs on the malad-
aptive behavior of mentally retarded individuals in residential
treatment settings.41 This inventory consists of 58 items that
address ﬁve dimensions of inappropriate and maladaptive18 EXPLORE January/February 2014, Vol. 10, No. 1behavior. These ﬁve factors have been conﬁrmed in several
studies.42,43 The dimensions of inappropriate and maladaptive
behavior measured by the ABC are as follows: Irritability (15
items), Lethargy (16 items), Stereotypy (7 items), Hyperactivity
(16 items), and Inappropriate Speech (4 items). Behaviors are
rated on a 4-point scale from 0 to 3, with higher scores
indicating more severity of the behavior speciﬁed.
In 1994, the authors of the ABC published the ABC-C, a
slightly modiﬁed version of the ABC with wording that
reﬂected community settings rather than institutional settings.44
The revision allowed the ABC to be used in research in a variety
of settings. The ABC-C uses the same ﬁve dimensions to rate
behavior as the ABC, and it was found to have the same
psychometric properties as the original version.45 Over 100
studies have used the ABC for measuring treatment outcomes
with pervasive developmental disorders and with children and
adults with intellectual disability. The ABC is considered to be
remarkably sensitive to treatment effects.46,47
ATEC
The Autism Treatment Evaluation Checklist (ATEC) was
developed by Rimland and Edelson48 and was designed
speciﬁcally to assist researchers, practitioners, and parents in
evaluating the efﬁcacy of any type of treatment used to treat
autism. The authors realized that most instruments that were
being used in autism research studies were developed to
diagnose autism and were not intended to measure gradations
of improvement. The use of such instruments in treatment
outcomes studies could overlook subtle changes, and as a
consequence lead to inconclusive or misleading results.49
The ATEC consists of 4 scales and a total score based on
the total of all 4 scales: (I) Speech/Language/Communication
(14 items, score range 0–28), (II) Sociability (20 items, score
range 0–40), (III) Sensory/Cognitive Awareness (18 items,
score range 0–36), and (IV) Health/Physical/Behavior (25
items, score range 0–75). The higher the score on each scale,
the more impairment is present in that area. The Total Score
for all 77 items can range from 0 to 179. A decline in scale
scores indicates improvement in that area. Split-half reliability
test analyses on 1358 completed ATECs indicated high
internal consistency reliabilities of both the scales and Total
ATEC score ranging from 81 to 94.31RESULTS
Primary Measures
Test data validated the hypotheses that children in the
experimental group would show signiﬁcant improvement as
measured by the PDDBI Autism Composite Index, ABC-C
Total Score, and the ATEC Total Score as a result of receivingIntention-Based Therapy for Autism Spectrum Disorder
12 sessions of NMT, that the wait-list control group would
show no signiﬁcant improvement on these measures during
the wait period, and that the wait-list control group would
show signiﬁcant improvement on these measures as a result of
receiving 12 sessions of NMT.
The experimental group showed signiﬁcant improvement
on all 3 primary outcome measures (PDDBI Autism Index,
p ¼ .0123; ABC-C Total Score, p ¼ .0022; and ATEC Total
Score, p ¼ .0025) (Table 2).
At the start of treatment for each group (Week 1 experi-
mental and Week 8 wait-list control), there was no difference
between groups on the PPDBI Autism Index and the ATEC
Total Score. The experimental group did have a higher score
on the ABC-C Total Score, p ¼.0219 (Table 3).
As expected, the wait-list control group showed no signiﬁ-
cant improvement on any of the primary measures as a result
of the eight week wait prior to receiving treatment (Table 4).
After receiving treatment, the wait-list control group
showed signiﬁcant improvement on all 3 primary outcome
measures (PDDBI Autism Index, p ¼ .0040; ABC-C Total
Score, p ¼ .0169; and ATEC Total Score, p ¼ .0077)
(Table 2).
Overall robust outcome measures and effect sizes were
obtained on all primary measures (Table 2).Secondary Measures
With regard to the secondary outcome measures, statistically
signiﬁcant improvement was seen in the experimental group
on 11 of 14 subscales of the PDDBI, 4 of 5 subscales of the
ABC-C, and all 4 subscales of the ATEC from pre-NMT
(Week 1) to post-NMT (Week 8). Experimental group
secondary outcomes are summarized below and in Figures
1–3.
Readers who are interested in a greater degree of detail on
the secondary outcome measures may contact the senior
author (RW).
As expected, the wait-list control group showed no signi-
ﬁcant improvement on any of the secondary outcomeFigure 1. Percentage change (improvement) on the PDDBI Autism Com
Experimental and Wait-List Control groups.
Intention-Based Therapy for Autism Spectrum Disordermeasures as a result of the eight week wait prior to receiving
treatment. Values on one subscale (Irritability) of the ABC-C
showed a signiﬁcant worsening (p ¼ .0384) as a result of
the wait.
Following treatment, statistically signiﬁcant improvement
was seen on 6 of 14 subscales of the PDDBI, 4 of 5 subscales
of the ABC-C, and 3 of 4 subscales of the ATEC from start of
treatment (Week 8) to post-NMT (Week 15). Wait-list
Control group secondary outcomes for each test instrument
are summarized below and in Figures 1–3.PDDBI
Signiﬁcant improvements in the following PDDBI subscales
were observed in the experimental group following treatment:
SENSORY (p ¼ .0213), RITUAL (p ¼ .0050), AROUSE (p ¼
.0498), FEARS (p ¼ .0156), SOCAPP (p ¼ .0270), EXPRESS
(p ¼ .0406), LMRL (p ¼ .0021), REPRIT/C (p ¼ .0151),
AWP/C (p ¼ .0130), EXCA/C (p ¼ .0123), and REXSCA/C
(p ¼ .0123) (Figure 1).
Signiﬁcant improvements in the following PDDBI sub-
scales were observed in the wait-list control group following
treatment: RITUAL (p ¼ .0221), SOCPP (p ¼ .0146), SEMPP
(p ¼ .0072), FEARS (p ¼ .0342), REPRIT/C (p ¼ .0096), and
AWP/C (p ¼ .0206) (Figure 1).ABC-C
Signiﬁcant improvements in the following ABC-C subscales
were observed in the experimental group following treatment:
Irritability (p ¼ .0014), Lethargy (p ¼ .0016), Stereotypy (p ¼
.0175), and Hyperactivity (p ¼ .0164) (Figure 2).
Signiﬁcant improvements in the following ABC-C sub-
scales were observed in the wait-list control group following
treatment: Irritability (p ¼ .0217), Lethargy (p ¼ .0294),
Stereotypy (p ¼ .0101), and Inappropriate Speech (p ¼
.0092) (Figure 2).posite and PDDBI subscales from start to end of treatment for the
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Figure 2. Percentage change (improvement) on the ABC-C Total Score and ABC-C subscales from start to end of treatment for the
Experimental and Wait-List Control groups.ATEC
Improvements in the following ATEC subscales were
observed in the experimental group following treatment:
Speech/language/communication (p ¼ .0072), Sociability
(p ¼ .0315), Sensory/cognitive awareness (p ¼ .0351), and
Health/physical/behavior (p ¼ .0001) (Figure 3).
Improvements in the following ATEC subscales were
observed in the wait-list control group following treatment:
Sociability (p ¼ .0133), Sensory/cognitive awareness (p ¼
.0111), and Health/physical/behavior (p ¼ .0211) (Figure 3).DISCUSSION
Children in both treatment groups responded very well to
NMT with signiﬁcant improvement in all primary outcomeFigure 3. Percentage change (improvement) on the ATEC Total Score an
and Wait-List Control groups.
20 EXPLORE January/February 2014, Vol. 10, No. 1measures and a majority of the secondary measures. Not only
were maladaptive behaviors such as irritability and hyper-
activity reduced but improvements were seen in adaptive
behaviors such as social approach behavior and expressive
language.
At the start of treatment, the experimental group had a
trend toward worse scores on all primary outcome measures as
well as on all secondary outcome measures than the wait-list
control group (non-signiﬁcant on all measures except on the
ABC-C Total Score, p ¼ .0219; ABC-C Stereotypy subscale,
p ¼ .0318; and the ABC-C Hyperactivity subscale, p ¼
.0141). This suggests that the experimental group as a whole
may have had slightly more severe autism symptoms than the
wait-list control group did before treatment began. On the
PDDBI, at the start of treatment, the experimental group notd ATEC subscales from start to end of treatment for the Experimental
Intention-Based Therapy for Autism Spectrum Disorder
only had higher scores than the wait-list control group did on
all subscales reﬂecting maladaptive behavior (reﬂecting more
severe symptoms) but it also had lower scores than the wait-
list control group did on all subscales reﬂecting adaptive
behavior (reﬂecting less adaptive behavior present). The
experimental group showed signiﬁcant improvement on all
5 of the adaptive subscales of the PDDBI following treatment,
whereas the wait-list control group did not signiﬁcantly
improve on any of these adaptive measures. The reason for
this difference may have been that the wait-list control group
was already functioning at a higher level in these areas to start
with, thereby leaving the experimental group with more room
for improvement.
An overall reduction in autism symptoms generally was
reﬂected by signiﬁcant decreases in the PDDBI Autism
Composite Index in both the experimental (p ¼ .0123) and
wait-list control groups (p ¼ .0040), as well as signiﬁcant
decreases on the ATEC Total Score, an index speciﬁcally
designed to measure autism treatment effects (p ¼ .0025 for
the experimental group and p ¼ .0077 for the wait-list control
group).
NMT does not address speciﬁc behaviors or diagnostic
classiﬁcations per se for correction or change but rather seeks
to improve overall internal organization so that changes in
speech, language, behavior, response to the environment, and
physiological functioning occur naturally. Treatment priority
is determined by the patient's need (as indicated by the
response to the MRT inquiries) and not by a pre-set treatment
plan. NMT does not suppress adaptive behaviors, something
that may occur with use of medications, which may have
sedating side effects.
NMT is easy to administer and imposes very little demand
on both the child and the therapist. NMT is a self-contained
treatment that can be administered to a child of any age. No
electrodes, wires, electronic devices, etc. are required to
administer it. At the same time, this treatment can comple-
ment and is compatible with all other forms of treatment a
child may be concurrently receiving. Children who receive
NMT tend not to view participating in a session as work or a
chore, as they are free to participate in a favorite behavior of
their choice during a session such as reading, playing video
games, or watching a DVD.
NMT differs from intention-based interventions that rely
on unidirectional intention such as prayers for healing of a
speciﬁc medical condition or prayers that simply seek recov-
ery when the medical condition is unknown or unspeciﬁed.
NMT is a true collaborative process where the patient
essentially directs the order of treatment through the MRT
process of therapist 2 patient communication on an
OTC level.
A traditional behavioral treatment for autism such as EIBI
is also a collaborative process between the therapist and child,
but such treatments require some degree of conscious
cooperation and attention from the child, and the course of
treatment progress can be painstakingly slow at times. Since
NMT is based on OTC communication between the therapist
and recipient, the attention or even the cooperation of the
child is neither required nor necessary for NMT to be
effective. This aspect of NMT enhances its efﬁcacy becauseIntention-Based Therapy for Autism Spectrum Disordera treatment can proceed without delay or loss of effectiveness
even if a child is in an uncooperative or deﬁant mood.
While speciﬁc clinical pathways (query and correction
statements/intentions structured on different clinical topics)
are used in an NMT treatment session, no standardized
session plans are used with NMT. The pathways used within
a session and the order of use of each pathway generally
change from session to session because the overall status of
the patient changes with each query and correction per-
formed. The patient presents with a constantly updating
status, and the MRT process used to determine the next
treatment pathway within a session is based in real time on
the most current status, not just the status of the patient when
he or she started the treatment session.
Implicit in the practice of NMT is the assumption that
therapeutic intention can be communicated on an OTC
basis, independent of the state of consciousness or coopera-
tion of the recipient. The ability of NMT to effectively bypass
the conscious minds of these children and direct a dialogue
with their OTC minds appears to account for the signiﬁcant
treatment gains seen in a relatively short amount of treatment
time (an average total length of treatment of only 9.2 hours).
This type of intention-based treatment facilitated communi-
cation within each child at a subconscious/OTC level in
order to produce more successful self-regulation, which in
turn led to a reduction in autism symptoms.
Follow-up NMT studies with this population should
include larger group sizes, use of third-party non-family
evaluators such as teachers, tutors, or therapists to provide
potentially more accurate ratings of change in different
environments, a longer period of treatment, additional
follow-up ratings to measure the persistence of observed
changes, and a placebo treatment group.CONCLUSION
The results from this preliminary study using NMT to
ameliorate symptoms of autism are very encouraging. This
study provides a foundation for future investigations on the
use of NMT as well as other intention-based interventions as
a treatment for complex neurodevelopmental disorders.Acknowledgments
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